Renaissance Technologies’s Cadrenal Therapeutics CVKD Stock Holding History

Renaissance Technologies’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,966	Closed	-$28K	–	3584
2024 Q2	$28K	Sell	3,966 -5,910	-60%	-$40.9K	﹤0.01%	3350
2024 Q1	$90K	Buy	9,876 +4,603	+87%	+$58.4K	﹤0.01%	3391
2023 Q4	$59K	Buy	+5,273	New	+$41.8K	﹤0.01%	3426

Other funds holding CVKD

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies's CVKD Position: Q3 2024 in Review

Renaissance Technologies sold out of Cadrenal Therapeutics (CVKD) in Q3 2024, closing a stake of 3,966 shares — an estimated $28K sold.

Renaissance Technologies first reported a position in CVKD in Q4 2023 and held it in 3 quarters. The position peaked at $90K in Q1 2024. 2 funds tracked by Wall St. Rank hold CVKD as of Q3 2024.

Renaissance Technologies reported no remaining Cadrenal Therapeutics position as of Q3 2024 after selling out during the quarter.
Renaissance Technologies sold 3,966 Cadrenal Therapeutics shares in Q3 2024, an estimated $28K.
Renaissance Technologies first reported a position in Cadrenal Therapeutics in Q4 2023 and held it in 3 quarters.
Renaissance Technologies's Cadrenal Therapeutics position peaked at $90K in Q1 2024.
2 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2024.

Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.